A manufacturing facility that Novartis discarded because of declining generics sales is getting a new life producing CBD products.

The FDA has raised questions about the manufacturing of Glenmark's new molecular entity Ryaltris, a nasal spray for seasonal allergic rhinitis.

Online pharmacy Valisure has criticized the FDA for what it deems as irrational standards in the levels of suspected carcinogens in the drug supply.

Bluebird Bio says the launch of Zynteglo, its first gene therapy, will not occur until 2020 while it tightens up its manufacturing processes.

Here is some more manufacturing news from the week.

Lyophilization Services of New England already has four facilities in the U.S. but has now jumped the Atlantic to pick up its first location in Europe.

Boehringer Ingelheim has invested €225 million on inhaler production with a new plant in Spain and expanded lines in Germany.

Generic pain drug maker Lannett is closing its plant in Wyoming and laying off the remaining 80 employees.